Growth of Value-Based Purchasing and Contracting for Cell & Gene Therapies

As a political power shift unfolds throughout the halls of Congress, the explosion of cell and gene therapies (CGTs) may be forcing employers to re-think coverage options and get more inventive in their approach to stop-loss coverage, policy limits and exclusions, and payment models. Innovative coverage options are emerging as employee demand accelerates for these costly but potentially lifesaving treatments.

Read the full article on page 8 here: March 2025 The Self-Insurer by The Self-Insurer Magazine